Meningococcal carriage in adolescents in the United Kingdom to inform timing of an adolescent vaccination strategy.

Autor: Jeppesen CA; Oxford Vaccine Group, Department of Paediatrics, University of Oxford and the NIHR Oxford Biomedical Research Centre, Oxford, UK. Electronic address: Catherine.jeppesen@dchft.nhs.uk., Snape MD; Oxford Vaccine Group, Department of Paediatrics, University of Oxford and the NIHR Oxford Biomedical Research Centre, Oxford, UK., Robinson H; Oxford Vaccine Group, Department of Paediatrics, University of Oxford and the NIHR Oxford Biomedical Research Centre, Oxford, UK., Gossger N; Oxford Vaccine Group, Department of Paediatrics, University of Oxford and the NIHR Oxford Biomedical Research Centre, Oxford, UK., John TM; Oxford Vaccine Group, Department of Paediatrics, University of Oxford and the NIHR Oxford Biomedical Research Centre, Oxford, UK., Voysey M; Primary Care Clinical Trials Unit, University of Oxford, Oxford, UK., Ladhani S; Health Protection Services, Immunisation, Hepatitis and Blood Safety Department, Public Health England, 61 Colindale Avenue, London, UK., Okike IO; Vaccine Institute & Paediatric Infectious Diseases Research Group, Division of Clinical Sciences, St George's, University of London, UK., Oeser C; Vaccine Institute & Paediatric Infectious Diseases Research Group, Division of Clinical Sciences, St George's, University of London, UK., Kent A; Vaccine Institute & Paediatric Infectious Diseases Research Group, Division of Clinical Sciences, St George's, University of London, UK., Oliver J; Bristol Children's Vaccine Centre, University of Bristol, School of Cellular and Molecular Medicine and University Hospitals Bristol NHS Foundation Trust, Bristol, UK., Taylor P; Bristol Children's Vaccine Centre, University of Bristol, School of Cellular and Molecular Medicine and University Hospitals Bristol NHS Foundation Trust, Bristol, UK., Morales-Aza B; Bristol Children's Vaccine Centre, University of Bristol, School of Cellular and Molecular Medicine and University Hospitals Bristol NHS Foundation Trust, Bristol, UK., Clarke SC; Academic Unit of Clinical and Experimental Sciences, Faculty of Medicine and Institute for Life Sciences, University of Southampton, Southampton, UK; Public Health England, Southampton, UK., Casey M; Southampton NIHR Wellcome Trust Clinical Research Facility, University Hospital Southampton NHS Foundation Trust, Southampton, UK., Martins F; Southampton NIHR Wellcome Trust Clinical Research Facility, University Hospital Southampton NHS Foundation Trust, Southampton, UK., Kitchin NR; Vaccine Research, Pfizer Ltd., Maidenhead, UK., Anderson AS; Vaccine Research, Pfizer Inc., Pearl River, NY, USA., Jones H; Vaccine Research, Pfizer Inc., Pearl River, NY, USA., Jansen KU; Vaccine Research, Pfizer Inc., Pearl River, NY, USA., Eiden J; Vaccine Research, Pfizer Inc., Pearl River, NY, USA., Pedneault L; Vaccine Research, Pfizer Inc., Pearl River, NY, USA., Heath PT; Vaccine Institute & Paediatric Infectious Diseases Research Group, Division of Clinical Sciences, St George's, University of London, UK., Finn A; Bristol Children's Vaccine Centre, University of Bristol, School of Cellular and Molecular Medicine and University Hospitals Bristol NHS Foundation Trust, Bristol, UK., Faust SN; Academic Unit of Clinical and Experimental Sciences, Faculty of Medicine and Institute for Life Sciences, University of Southampton, Southampton, UK; Southampton NIHR Wellcome Trust Clinical Research Facility, University Hospital Southampton NHS Foundation Trust, Southampton, UK., Pollard AJ; Oxford Vaccine Group, Department of Paediatrics, University of Oxford and the NIHR Oxford Biomedical Research Centre, Oxford, UK.

Publikováno v: The Journal of infection [J Infect] 2015 Jul; Vol. 71 (1), pp. 43-52. Date of Electronic Publication: 2015 Feb 21.

Response to Berrington JE, et al. "Reduced anti-PRP antibody response to Hib immunisation in pre-term (<32 weeks) UK infants who received inactivated polio (eIPV)" [Vaccine 2007; 25(49): 8206-8].

Autor: Kitchin NR, Reynolds DL

Publikováno v: Vaccine [Vaccine] 2008 Mar 10; Vol. 26 (11), pp. 1405-6. Date of Electronic Publication: 2008 Jan 31.

Costs of running a universal adolescent hepatitis B vaccination programme.

Autor: Wallace LA; Health Protection Scotland, Clifton House, Clifton Place, Glasgow G3 7LN, UK. lesley.Wallace@hps.scot.nhs.uk, Young D, Brown A, Cameron JC, Ahmed S, Duff R, Carman WF, Kitchin NR, Nguyen-Van-Tam JS, Goldberg DJ

Publikováno v: Vaccine [Vaccine] 2005 Dec 01; Vol. 23 (48-49), pp. 5624-31. Date of Electronic Publication: 2005 Jul 27.

Determinants of universal adolescent hepatitis B vaccine uptake.

Autor: Wallace LA; Scottish Centre for Infection and Environmental Health, Clifton House, Clifton Place, Glasgow G3 7LN, UK. Lesley.Wallace@scieh.csa.scot.nhs.uk, Bramley JC, Ahmed S, Duff R, Hutchinson SJ, Carman WF, Kitchin NR, Goldberg DJ

Publikováno v: Archives of disease in childhood [Arch Dis Child] 2004 Nov; Vol. 89 (11), pp. 1041-2.

Universal hepatitis B vaccination of UK adolescents: a feasibility and acceptability study.

Autor: Bramley JC; Scottish Centre for Infection and Environmental Health, Clifton House, Clifton Place, Glasgow G3 7LN. claire.bramley@scieh.csa.scot.nhs.uk, Wallace LA, Ahmed S, Duff R, Carman WF, Cameron SO, Kitchin NR, Watson MW, Goldberg DJ

Publikováno v: Communicable disease and public health [Commun Dis Public Health] 2002 Dec; Vol. 5 (4), pp. 318-20.